西格列汀联合二甲双胍治疗2型糖尿病的临床效果  

Clinical efficacy of sitagliptin combined with metformin in the treatment of T2DM

作　　者：赖彦希 李琼[2] 钟伟章[1] 罗玉钊[1] 黎燕霞 LAI Yanxi;LI Qiong;ZHONG Weizhang;LUO Yuzhao;LI Yanxia(Department of Pharmacy,the People’s Hospital of Gaozhou,Guangdong,Gaozhou 525200,China;Department of Endocrinology,the People’s Hospital of Gaozhou,Guangdong,Gaozhou 525200,China)

机构地区：[1]广东省高州市人民医院药剂科,广东高州525200 [2]广东省高州市人民医院内分泌科,广东高州525200

出　　处：《中国医药科学》2022年第13期131-134,共4页China Medicine And Pharmacy

摘　　要：目的 分析西格列汀联合二甲双胍治疗2型糖尿病(T2DM)的临床疗效。方法 选取高州市人民医院内分泌科2020年1月至2021年1月接诊的80例T2DM患者,根据随机数字表法分组,每组各40例,比较组接受二甲双胍治疗,观察组接受西格列汀联合二甲双胍治疗。治疗2个月后,比较两组临床疗效,观察两组血糖指标、血糖达标时间、胰岛β细胞功能指标、氧化应激指标、不良反应总发生率。结果 观察组患者的临床总有效率为95.00%,高于比较组的72.50%,观察组患者治疗后的空腹血糖(FBG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 hPG)、胰岛素抵抗指数(HOMA-IR)、血清丙二醛(MDA)均低于比较组,观察组患者治疗后的胰岛β细胞功能指数(HOMA-β)、血清谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)均高于比较组,观察组患者的血糖达标时间短于比较组,差异均有统计学意义(P <0.05)。观察组患者的不良反应总发生率为7.50%,与比较组的5.00%比较,差异无统计学意义(P> 0.05)。结论 西格列汀联合二甲双胍可有效降低T2DM患者血糖值,缩短血糖达标时间,改善胰岛β细胞功能,减轻氧化应激反应,且联合给药并未增加不良反应。Objective To analyze the clinical efficacy of sitagliptin combined with metformin in the treatment of type 2 diabetes mellitus(T2DM). Methods A total of 80 patients with T2DM who attended the Department of Endocrinology in the People’s Hospital of Gaozhou from January 2020 to January 2021 were selected as study subjects and grouped according to the random number table method, with 40 patients in each group. The comparison group was treated with metformin, while the observation group was treated with sitagliptin combined with metformin. After 2 months of treatment, the clinical efficacy, glycemic index, time for blood glucose reaching the standard, islet β cell function index, oxidative stress index, and the total incidence of adverse reactions were compared between the two groups. Results The overall clinical effective rate in the observation group(95.00%) was higher than that in the comparison group(72.50%). The levels of fasting blood-glucose(FBG), glycosylated hemoglobin(HbA1c), 2-hour postprandial glucose(2 hPG), homeostasis model assessmentinsulin resistance(HOMA-IR) and serum malondialdehyde(MDA) in the observation group were lower than those in the comparison group after treatment, and homeostasis model assessment-β(HOMA-β) index, levels of serum glutathione peroxidase(GSH-Px) and superoxide dismutase(SOD) in the observation group were higher than those in the comparison group, and the time for blood glucose reaching the standard in the observation group was shorter than that in the comparison group, all with statistically significant differences(P < 0.05).There was no statistically significant difference between the observation group(7.50%) and the comparison group(5.00%) in the total incidence of adverse reactions(P > 0.05). Conclusion Sitagliptin combined with metformin can effectively decrease blood glucose levels, shorten the time for blood glucose to reach the standard, improve islet β cell function and reduce oxidative stress in patients with T2DM, and the combined administration does not incr

关 键 词：西格列汀 二甲双胍 2型糖尿病 临床疗效 

分 类 号：R587.1[医药卫生—内分泌]